Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: Are we there yet?

Expert Review of Vaccines

Volumn 6, Issue 3, 2007, Pages 431-440

  Lewis, George K ^a  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

Adaptive immunity; Bacterial immunity; Bacterial vector vaccines; DNA vaccine; Innate immunity; Metabolic balancing; Salmonella; Transfection; Vaccine

Indexed keywords

ANTIGEN; BCG VACCINE; CHOLERA VACCINE; DNA VACCINE; DRUG VEHICLE; GLYCOPROTEIN GP 120; LIVE VACCINE; SALMONELLOSIS VACCINE; TYPHOID VACCINE;

ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; BACTERIAL STRAIN; DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; MUTAGENESIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SALMONELLA; SALMONELLA TYPHIMURIUM; SHIGELLA; TUBERCULOSIS;

ADMINISTRATION, ORAL; ANIMALS; BACTERIAL VACCINES; HUMANS; SALMONELLA VACCINES; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 34250374367     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.3.431     Document Type: Review

References (80)

1. Plotkin SL, Plotkin SA. A short history of vaccination. In: Vaccines. Plotkin SA, Orenstein WA (Eds). Saunders, PA, USA 1-15 (2004).
2. Germanier R, Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131(5), 553-558 (1975). • Describes the original isolation and characterization of the Ty21a typhoid vaccine strain.
3. Kaper JB, Levine MM. Cloned cholera enterotoxin genes in study and prevention of cholera. Lancet 2(8256), 1162-1163 (1981).
4. Kaper JB, Lockman H, Baldini MM, Levine MM. Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature 308(5960), 655-658 (1984). •• First report using recombinant DNA methods to develop a live-attenuated bacterial vaccine by removing a virulence factor.
5. Levine MM, Kaper JB, Herrington D et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 2(8609), 467-470 (1988).
6. Tacket CO, Losonsky G, Nataro JP et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166(4), 837-841 (1992).
7. Chatfield SN, Fairweather N, Charles I et al. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine 10(1), 53-60 (1992).
8. Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 9(11), 810-816 (1991).
9. Roland KL, Tinge SA, Killeen KP, Kochi SK. Recent advances in the development of live, attenuated bacterial vectors. Curr. Opin. Mol. Ther. 7(1), 62-72 (2005).
10. Dietrich G, Spreng S, Favre D, Viret JF, Guzman CA. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines. Curr. Opin. Mol. Ther. 5(1), 10-19 (2003).
11. Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM. Recent advances with recombinant bacterial vaccine vectors. Mol. Med. Today 6(2), 66-71 (2000).
12. Brown A, Hormaeche CE, Demarco de Hormaeche R et al. An attenuated aroA Salmonella typhimurium vaccine elicits humoral and cellular immunity to cloned ?-galactosidase in mice. J. Infect. Dis. 155(1), 86-92 (1987).
13. Gonzalez C, Hone D, Noriega FR et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169(4), 927-931 (1994).
14. + cytotoxic T cells. J. Exp. Med. 172(4), 1083-1090 (1990).
15. Sadoff JC, Ballou WR, Baron LS et al. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240(4850), 336-338 (1988).
16. Russmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 281(5376), 565-568 (1998). •• First study to illustrate the use of type III secretion systems for the delivery of pasenger antigens.
17. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270(5234), 299-302 (1995). •• First report of DNA delivery to eukaryotic cells by attenuated Shigella.
18. Galen JE, Pasetti MF, Sztein MB, Barry EM, Levine MM. Attenuated Salmonella and Shigella as live vectors carrying either prokaryotic or eukaryotic expression systems. In: New Generation Vaccines. Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MA (Eds). Marcel Dekker, NY, USA 353-365 (2004).
19. Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MA. New Generation Vaccines. Marcel Dekker, NY, USA (2004). •• One of the two most complete reviews of vaccinology with emphasis on modern (postrecombinant DNA era) approaches to vaccine development.
20. Plotkin SA, Orenstein WA, Offit PA. Vaccines Saunders, PA, USA (2004). •• One of the two most complete reviews of vaccinology that complements those in [19] where there is a strong emphasis on the historical elements of vaccine development.
21. Clements JD, El-Morshidy S. Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect. Immun. 46(2), 564-569 (1984).
22. Newton SM, Jacob CO, Stocker BA. Immune response to cholera toxin epitope inserted in Salmonella flagellin. Science 244(4900), 70-72 (1989). • Seminal report of modifying a bacterial surface protein to deliver a heterologous epitiope.
23. Su GF, Brahmbhatt HN, de Lorenzo V, Wehland J, Timmis KN. Extracellular export of Shiga toxin B-subunit/haemolysin A (C-terminus) fusion protein expressed in Salmonella typhimurium aroA-mutant and stimulation of B-subunit specific antibody responses in mice. Microb. Pathog. 13(6), 465-476 (1992).
24. Gentschev I, Mollenkopf HJ, Sokolovic Z et al. Synthesis and secretion of bacterial antigens by attenuated Salmonella via the Escherichia coli hemolysin secretion system. Behring Inst. Mitt. (95), 57-66 (1994).
25. Lo RY, Watt MA, Gyroffy S, Mellors A. Preparation of recombinant glycoprotease of Pasteurella haemolytica A1 utilizing the Escherichia coli α-hemolysin secretion system. FEMS Microbiol. Lett. 116(2), 225-230 (1994).
26. Tacket CO, Forrest B, Morona R et al. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect. Immun. 58(6), 1620-1627 (1990).
27. Fairweather NF, Chatfield SN, Makoff AJ et al. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier. Infect. Immun. 58(5), 1323-1326 (1990).
28. Poirier TP, Kehoe MA, Beachey EH. Protective immunity evoked by oral administration of attenuated aroA Salmonella typhimurium expressing cloned streptococcal M protein. J. Exp. Med. 168(1), 25-32 (1988).
29. Tite JP, Gao XM, Hughes-Jenkins CM et al. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. III. Delivery of recombinant nucleoprotein to the immune system using attenuated Salmonella typhimurium as a live carrier. Immunology 70(4), 540-546 (1990).
30. Stone JL. On the mode of release of tetanus toxin from the bacterial cell. J. Bacteriol. 67(1), 110-116 (1954).
31. Fouts TR, Lewis GK, Hone DM. Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine. Vaccine 13(6), 561-569 (1995).
32. Fouts TR, Tuskan RG, Chada S, Hone DM, Lewis GK. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. Vaccine 13(17), 1697-1705 (1995).
33. Wu S, Pascual DW, Lewis GK, Hone DM. Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector. AIDS Res. Hum. Retroviruses 13(14), 1187-1194 (1997).
34. Berggren RE, Wunderlich A, Ziegler E et al. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10(5), 489-495 (1995).
35. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18(5-6), 449-459 (1999).
36. Londono-Arcila P, Freeman D, Kleanthous H et al. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect. Immun. 70(9), 5096-5106 (2002).
37. Metzger WG, Mansouri E, Kronawitter M et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar Typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 22(17-18), 2273-2277 (2004).
38. Tacket CO, Galen J, Sztein MB et al. Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol. 97(2), 146-153 (2000).
39. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68(4), 2135-2141 (2000).
40. Tacket CO, Kelly SM, Schodel F et al. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun. 65(8), 3381-3385 (1997).
41. Makrides SC. Strategies for achieving highlevel expression of genes in Escherichia coli. Microbiol. Rev. 60(3), 512-538 (1996).
42. Hess J, Gentschev I, Miko D et al. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc. Natl Acad. Sci. USA 93(4), 1458-1463 (1996). •• Seminal report showing that secreted passenger antigens are more immunogenic than those expressed somatically in the bacterial vector.
43. Galen JE, Levine MM. Can a 'flawless' live vector vaccine strain be engineered? Trends Microbiol. 9(8), 372-376 (2001).
44. Jagusztyn-Krynicka EK, Clark-Curtiss JE, Curtiss R 3rd. Escherichia coli heat-labile toxin subunit B fusions with Streptococcus sobrinus antigens expressed by Salmonella typhimurium oral vaccine strains: importance of the linker for antigenicity and biological activities of the hybrid proteins. Infect. Immun. 61(3), 1004-1015 (1993).
45. Coulson NM, Fulop M, Titball RW. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine 12(15), 1395-1401 (1994).
46. Haddad D, Liljeqvist S, Kumar S et al. Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol. Med. Microbiol. 12(3-4), 175-186 (1995).
47. Newton SM, Kotb M, Poirier TP, Stocker BA, Beachey EH. Expression and immunogenicity of a streptococcal M protein epitope inserted in Salmonella flagellin. Infect. Immun. 59(6), 2158-2165 (1991).
48. + memory T cells and long lasting protection following immunization with Salmonella typhimurium expressing a lymphocytic choriomeningitis MHC class I-restricted epitope. Vaccine 20(3-4), 577-585 (2001).
49. Kotton CN, Lankowski AJ, Scott N et al. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine 24(37-39), 6216-6224 (2006).
50. Evans DT, Chen LM, Gillis J et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J. Virol. 77(4), 2400-2409 (2003).
51. Vindurampulle CJ, Cuberos LF, Barry EM, Pasetti MF, Levine MM. Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy. Vaccine 22(27-28), 3744-3750 (2004).
52. Lasaro MO, Luiz WB, Sbrogio-Almeida ME, Ferreira LC. Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli. Vaccine 23(19), 2430-2438 (2005).
53. Courvalin P, Goussard S, Grillot-Courvalin C. Gene transfer from bacteria to mammalian cells. CR Acad. Sci. III 318(12), 1207-1212 (1995).
54. Hone DM, Wu S, Powell RJ et al. Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. J. Biotechnol. 44(1-3), 203-207 (1996).
55. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine 15(8), 804-807 (1997).
56. Darji A, Guzman CA, Gerstel B et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91(6), 765-775 (1997).
57. Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 92(9), 3172-3176 (1998).
58. Schoen C, Stritzker J, Goebel W, Pilgrim S. Bacteria as DNA vaccine carriers for genetic immunization. Int. J. Med. Microbiol. 294(5), 319-335 (2004).
59. Daudel D, Weidinger G, Spreng S. Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev. Vaccines 6(1), 97-110 (2007).
60. Devico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM. Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 20(15), 1968-1974 (2002).
61. Galen JE, Nair J, Wang JY et al. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect. Immun. 67(12), 6424-6433 (1999).
62. Bauer H, Darji A, Chakraborty T, Weiss S. Salmonella-mediated oral DNA vaccination using stabilized eukaryotic expression plasmids. Gene Ther. 12(4), 364-372 (2005).
63. Gahan ME, Webster DE, Wesselingh SL, Strugnell RA. Impact of plasmid stability on oral DNA delivery by Salmonella enterica serovar Typhimurium. Vaccine 25(8), 1476-1483 (2007).
64. Cicin-Sain L, Brune W, Bubic I, Jonjic S, Koszinowski UH. Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo. J. Virol. 77(15), 8249-8255 (2003).
65. Pasetti MF, Barry EM, Losonsky G et al. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J. Virol. 77(9), 5209-5217 (2003).
66. Goussard S, Grillot-Courvalin C, Courvalin P. Eukaryotic promoters can direct protein synthesis in Gram-negative bacteria. J. Mol. Microbiol. Biotechnol. 6(3-4), 211-218 (2003).
67. Woo PC, Tsoi HW, Leung HC, Yuen KY. Enhancement of humoral and protective immune response induced by live-attenuated Salmonella typhi by ampicillin. Apmis 108(5), 343-348 (2000).
68. Garmory HS, Brown KA, Titball RW. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol. Rev. 26(4), 339-353 (2002).
69. Castagliuolo I, Beggiao E, Brun P et al. Engineered E. coli delivers therapeutic genes to the colonic mucosa. Gene Ther. 12(13), 1070-1078 (2005).
70. Jain V, Mekalanos JJ. Use of λ phage S and R gene products in an inducible lysis system for Vibrio cholerae- and Salmonella enterica serovar Typhimurium-based DNA vaccine delivery systems. Infect. Immun. 68(2), 986-989 (2000).
71. Dietrich G, Hess J, Gentschev I, Knapp B, Kaufmann SH, Goebel W. From evil to good: a cytolysin in vaccine development. Trends Microbiol. 9(1), 23-28 (2001).
72. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4(11), 868-877 (2004).
73. Malim MH. Natural resistance to HIV infection: The Vif-APOBEC interaction. CR Biol. 329(11), 871-875 (2006).
74. Chiu YL, Witkowska HE, Hall SC et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl Acad. Sci. USA 103(42), 15588-15593 (2006).
75. Salzberg SL, White O, Peterson J, Eisen JA. Microbial genes in the human genome: lateral transfer or gene loss? Science 292(5523), 1903-1906 (2001).
76. Stanhope MJ, Lupas A, Italia MJ, Koretke KK, Volker C, Brown JR. Phylogenetic analyses do not support horizontal gene transfers from bacteria to vertebrates. Nature 411(6840), 940-944 (2001).
77. Genereux DP, Logsdon JM Jr. Much ado about bacteria-to-vertebrate lateral gene transfer. Trends Genet. 19(4), 191-195 (2003).
78. Diaz-Garcia FJ, Herrera-Mendoza AP, Giono-Cerezo S, Guerra-Infante FM. Mycoplasma hominis attaches to and locates intracellularly in human spermatozoa. Hum. Reprod. 21(6), 1591-1598 (2006).
79. Fenn K, Blaxter M. Wolbachia genomes: revealing the biology of parasitism and mutualism. Trends Parasitol. 22(2), 60-65 (2006).
80. Chen LM, Briones G, Donis RO, Galan JE. Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development. Infect. Immun. 74(10), 5826-5833 (2006).